Cancer Diagnosis Associated With Increased Risk of Adverse Financial Events

Article

Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.

Adverse financial effects (AFEs) and past-due credit card payments were found to be more prevalent in patients who have received a cancer diagnosis, although more information is needed to determine how this relate to treatment decisions and quality of life, according to a study published in the Journal of Clinical Oncology.

When age, sex, average baseline credit, area deprivation index, and diagnosis year was adjusted, patients with cancer had a higher risk of AFEs (OR, 1.71; 95% CI, 1.61-1.81; P <.0001), as well as past-due credit payments (OR, 1.28; 95% CI, 1.19-1.37; P <.0001) compared with those in the control group.

A total of 190,722 patients were identified from either Western Washington SEER cancer registry and included 63,574 cases and a random sample of voter registry records known as controls of 127,148.

More patients in the cases group had an unknown area deprivation index compared with the control group. Notably, the distribution of cases and controls across different area deprivation index categories was similar, although a small proportion of individuals in both groups resided in high area deprivation index neighborhoods. A lower baseline of available credit was observed in the cases group, with an average mean credit line of $12,486. In total, 13.8% of patients were Black.

At 24 months, there was evidence of more AFEs (4.3% vs 2.4%; P <.0001) and higher rates of past-due credit card payments (2.6% vs 1.9%; P <.0001) in the cases group compared with the control group. Additionally, more patients who were Black experienced AFEs than those who were not (15.2% vs 4.2%; P <.0001) in the cases vs controls group, respectively.

The most common AFEs were third-party collections, charge-offs, and delinquent mortgage payments. However, foreclosures and repossessions were less common. In the cases group, all events were more common, with the exception of foreclosures and liens which were uncommon and not significantly higher in the cancer population.

Patients who had received a cancer diagnosis were associated with all AFE severity types following adjustment, including severe AFE (OR, 1.87; 95% CI, 1.76-1.99), more severe AFE (OR, 1.23; 95% CI, 1.08-1.40), and most severe AFE (OR, 1.45; 95% CI, 1.04-2.02). A subgroup consisting of 5-year cancer survivors with matched controls showed a greater proportion of both groups experienced AFE, but those with cancer remained at an increased risk at 9.0% and 6.1% in the control group (OR, 1.41; 95% CI, 1.32-1.50; P <.0001).

The sensitivity analysis found the mean number of prior AFEs was 0.26 in the cases group compared with 0.16 in the control group. Patients in the cases group had a lower baseline available credit of $9,716 vs $11,136 in the control group (P <.0001).

Additionally, a separate analysis was conducted that included patients who died within 24 months of diagnosis. The analysis found that 5.3% of patients with cancer had AFEs post-diagnosis compared with 4.3% of those with cancer who survived after 24 months. The logistic regression analysis found those with cancer had an increased risk of AFEs compared with those in the controls (OR, 2.19; 95% CI, 2.1-2.3; P <.0001).

Reference

Shankaran V, Li L, Fedorenko C, et al. Risk of adverse financial events in patients with cancer: evidence from a novel linkage between cancer registry and credit records. J Clin Oncol. 2022;40(8):884-891. doi:10.1200/JCO.21.01636

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content